Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information communication from GlaxoSmithKline: comparative data have shown that lapatinib based regimens are less effective than Herceptin© (trastuzumab) based regimens in certain settings.
Important Safety Information - Tyverb© (lapatinib)